What caused the ABT.SW stock volume spike on 13 Jan 2026?

The spike was flagged by a relative-volume metric at **40.00x** versus avgVolume **1**, indicating abnormal order flow. Market drivers include short-term interest ahead of Abbott’s earnings on 22 Jan 2026 and rotation into healthcare device names.

What are near-term price targets for ABT.SW stock?

Meyka AI’s model sets a quarterly target of **CHF108.20** (+8.20% vs CHF100.00) and a 12‑month projection of **CHF98.33** (-1.67% vs CHF100.00). Targets are model projections and not guarantees.

How does ABT.SW stock look on fundamentals and valuation?

Abbott shows EPS **6.32**, P/E **15.82**, price‑to‑sales **4.98**, ROE **28.24%**, and dividend yield **1.97%**. These metrics indicate solid profitability and mid‑teens valuation versus peers.

How should traders use the ABT.SW stock volume signal?

Treat the volume spike as a short‑term alert for possible follow‑through. Use defined-risk entries near **CHF100.00**, stops around **CHF97.00**, and profit targets near **CHF106.00** and **CHF108.20**, adjusting for earnings risk.

CH Stocks

ABT.SW Abbott Laboratories (SIX) volume spike 13 Jan 2026: CHF100 key

ByHuzaifa Zahoor January 14, 2026January 14, 2026

ABT.SW stock showed a volume-spike signal on 13 Jan 2026, trading at CHF100.00 on the SIX market after a +1.01% close. Meyka AI flagged a relative volume reading of 40.00x versus an average volume of 1 share, marking a short-term liquidity event. With EPS 6.32 and P/E 15.82, the market is pricing Abbott Laboratories for steady earnings. We examine what the spike means for price levels, near-term catalysts and technical support around CHF100.00 ahead of the 22 Jan 2026 earnings release